UNSPSC 51142547: Bromocriptine methanesulfonate

This classification denotes a neuroprotective agent with the molecular formula C32H40BrN5O5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FFP983J3OD, chemically known as ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'.alpha.)-, but more generally known as bromocriptine methanesulfonate, which bears US NIH Compound Identifier 31100.

European Medicines Agency schedules bromocriptine methanesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05918MIG. Most nations, for tariff purposes, schedule bromocriptine methanesulfonate under HS 29396900. SMILES: CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6C7C(CCCC7[NH]C6BR)C5=C4)C)O.CS(=O)(=O)O.

UNSPSC 51142547 Bromocriptine methanesulfonate is a Commodity code that represents a specific pharmaceutical product, but recent state and local solicitations tagged to this code show little alignment with bromocriptine procurement itself. The most recent opportunities instead involve broader pharmaceutical and healthcare product acquisition — naloxone and drug deactivation systems, direct-to-manufacturer pharmacy benefit programs, and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing. This mismatch suggests the code sees limited targeted activity for bromocriptine specifically; when state and local bodies procure pharmaceutical commodities, they typically do so through broader aggregated frameworks rather than single-product codes.

Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (MMCAP, administered by the Minnesota Department of Administration). Geographic activity spans Florida, Texas, Minnesota, and Oregon through the cooperative vehicle. Representative recent opportunities include Seminole County's IFB 60459723LAS for naloxone and drug deactivation systems with a response deadline of July 26, 2023; the Texas HHS Commission's RFI HHS0017013 for direct-to-manufacturer prescription program capabilities, due April 3, 2026; and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products across participating jurisdictions, due March 26, 2026. The cooperative purchasing vehicle and multi-jurisdiction scope suggest that state and local pharmaceutical procurement increasingly consolidates demand through aggregated contracts rather than individual commodity codes.